Azienda Sanitaria Universitaria Friuli Centrale
Welcome,         Profile    Billing    Logout  
 19 Trials 
88 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lee
NCT05509868: Study of PBK_L1704 for the Treatment of Moderate to Severe Acute Pain After Bunionectomy in South Korea

Recruiting
3
225
RoW
PBK_L1704 0.35mg, PBK_L1704 0.5mg, Placebo
Pharmbio Korea Co., Ltd.
Acute Pain
12/22
12/22
STAMP, NCT05529056: Study of Atropine Therapeutic Effect on Myopic Progression

Recruiting
3
472
RoW
Atropine Sulfate 01, LPTAT01, Atropine Sulfate 02, LPTAT02, Atropine Sulfate 03, LPTAT03, Placebo, LPTAT04
LitePharmTech Co., Ltd.
Myopia, Children
06/23
12/23
NCT05128344 / 2021-003015-26: A Study to Evaluate Safety and Efficacy of AMZ002 Treatment, Compared With Vigabatrin in Participants With Infantile Spasms

Withdrawn
3
150
Europe, US, RoW
AMZ002 injectable solution, 0.5mg/mL, Vigabatrin, oral
Amzell
Spasms, Infantile
06/25
12/25
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1594
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32
CARTITUDE-6, NCT05257083 / 2021-003284-10: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Recruiting
3
750
Europe, Canada, Japan, US, RoW
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, JNJ-68284528, Cyclophosphamide, Fludarabine
Stichting European Myeloma Network, Janssen Research & Development, LLC
Multiple Myeloma
06/33
08/40
NCT05733624: Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis

Completed
2
116
RoW
SCAI-001 0.01% eyedrop, Cyclosporine 0.01%, SCAI-001 0.02% eyedrop, Cyclosporine 0.02%, Restasis 0.05% eyedrop, Cyclosporine 0.05%
SCAI Therapeutics
Dry Eye Syndromes
08/23
02/24
PLATINUM, NCT05338619: A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy

Recruiting
2
77
RoW
Lazertinib, LECLAZA
Sung Yong Lee, Yuhan Corporation
Non-small Cell Lung Cancer Stage III, EGFR Positive Non-small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer
03/26
03/26
WU-KONG1, NCT03974022: Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer with EGFR or HER2 Mutation

Active, not recruiting
1/2
315
Europe, Canada, Japan, US, RoW
Sunvozertinib, DZD9008
Dizal Pharmaceuticals
Non-Small Cell Lung Cancer
07/24
07/25
JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL

Completed
1/2
171
US, RoW
golidocitinib, AZD4205
Dizal Pharmaceuticals
Relapsed or Refractory Peripheral T Cell Lymphoma
10/23
02/24
NCT04746573: Effect of Natrox Oxygen Wound Therapy on Non-healing Wounds and Implication of Remote Monitoring and Telehealth for Management in the Home.

Completed
N/A
8
US
Natrox Topical Oxygen Therapy
Inotec AMD Limited, Salem VA Medical Center
Non-healing Wounds
05/22
05/22
JS-CT-2024-02, NCT06591221: The Effectiveness of Chuna Maintenance Therapy for Chronic Bothersome Neck Pain

Recruiting
N/A
250
RoW
Chuna Maintenance Therapy
Jaseng Medical Foundation
Neck Pain, Chronic Pain
12/25
12/25
ATEC.EOS-2402, NCT06659055: Bone Mineral Density Agreement Study Between EOSedge™ Versus Traditional DXA

Recruiting
N/A
214
US
DXA Imaging, EOSedge imaging
Alphatec Spine, Inc.
Healthy, Indicated for EOSedge Imaging
02/25
03/25
JS-CT-2024-04, NCT06572579: A Pilot Registry for Ultrasound-guided Pharmacopuncture

Recruiting
N/A
50
RoW
Ultrasound-guided pharmacopuncture treatment
Jaseng Medical Foundation
Neck Pain, Back Pain
12/25
12/25
NCT04701684: WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)

Recruiting
N/A
564
Europe, US, RoW
Direct to Angio Suite (DTAS) Philips' CBCT triage, Conventional CT/MR triage
Philips Clinical & Medical Affairs Global
Stroke, Acute
12/25
12/25
NCT06734858: Pivotal Trial of SAT-014 for Trauma and Stressor-Related Disorder Symptoms

Recruiting
N/A
110
RoW
SAT014, Control
S-Alpha Therapeutics, Inc.
Post-traumatic Stress Disorder, Adjustment Disorders
07/25
10/25
SAT001-KP-003, NCT06742268: Extension Study on Safety and Rebound Effect of SAT-001 for Myopia in Children

Recruiting
N/A
40
RoW
Single vision spectacles
S-Alpha Therapeutics, Inc.
Myopia
10/25
07/26
Minisini, Alessandro
NCT05299580 / 2019-004760-21: "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

Withdrawn
2
35
Europe
dabrafenib, Trametinib
Fondazione Melanoma Onlus, Novartis Farma S.p.A.
Melanoma
03/23
03/23
OVERTuRE, NCT06129786: Overcoming Therapy Resistance in ER+ Breast Cancer Patients: a Translational Project

Recruiting
N/A
74
Europe
Centro di Riferimento Oncologico - Aviano
Breast Cancer
05/26
05/26
Tamberi, Stefano
SAGITTARIUS, NCT06490536: The Sagittarius Trial

Recruiting
3
700
Europe
Oxaliplatin, Capecitabine, Folinic acid, Fluorouracil, Temozolomide, Irinotecan, Nivolumab, Ipilimumab, Trastuzumab, Pertuzumab, Panitumumab
IFOM ETS - The AIRC Institute of Molecular Oncology
Colon Cancer Stage II, Colon Cancer Stage III
03/26
09/28
PANThEON, NCT06897644: Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

Recruiting
3
340
Europe
Oxaliplatin, Irinotecan (CPT-11), Leucovorin, 5-FU (5-fluorouracil), gemcitabine, Nab-paclitaxel
Gruppo Oncologico del Nord-Ovest, Rising Tide Foundation
Pancreatic Adenocarcinoma Advanced or Metastatic
01/29
01/30
DOMENICA, NCT05201547 / 2021-002124-21: Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Recruiting
3
260
Europe, Canada, Japan, RoW
Carboplatin-Paclitaxel, Dostarlimab
ARCAGY/ GINECO GROUP, GlaxoSmithKline
Endometrial Cancer
04/26
10/29
PURITY, NCT06037980: CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

Recruiting
2/3
300
Europe
Gemcitabine, Nab paclitaxel, Abraxane, Cisplatin, Curative Surgery, Capecitabine
Gruppo Oncologico del Nord-Ovest
Biliary Tract Cancer, Cholangiocarcinoma
12/28
01/29
SENECA, NCT03387592 / 2016-000767-17: CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas

Terminated
2
53
Europe
CPT-11, Calcio levofolinate, 5-Fluorouracil, Capecitabine, Temozolomide
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Neuroendocrine Carcinoma
02/22
02/22
PANDORA, NCT04083365: Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer

Recruiting
2
100
Europe
Capecitabine, Radiotherapy, Durvalumab
AUSL Romagna Rimini, AstraZeneca, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
RECTAL CANCER
11/22
08/25
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Hourglass Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
Hourglass Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
Hourglass Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
Hourglass Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer
Completed
2
79
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IMGN853
AbbVie
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
01/24
12/24
BRICKET, NCT06578559: Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC

Recruiting
2
16
Europe
Cetuximab, Encorafenib
Gruppo Oncologico del Nord-Ovest, Merck Sharp & Dohme LLC, Pierre Fabre Laboratories
Colorectal Cancer
08/26
04/27
ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting
2
400
Europe
Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib
Fondazione per la Medicina Personalizzata
Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
12/24
06/25
ERASE-CRC, NCT05062889: Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

Recruiting
2
477
Europe
5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5FU, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule, Oxaliplatin FOLFOX and FOLFOXIRI schedule, Oxa, Oxaliplatin CAPOX schedule, L-Leucovorin, Lederfolin, Capecitabine, Irinotecan, Trifluridine/Tipiracil, FTD/TPI, Trastuzumab, Tucatinib
Gruppo Oncologico del Nord-Ovest, Servier, Foundation Medicine, Seagen Inc.
Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer, RAS Wild-type Colon Cancer
10/25
12/27
OVERPASS, NCT05861336 / 2022-001939-88: GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer

Withdrawn
2
34
Europe
Losartan, Gemcitabine, Nab paclitaxel, Stereotactic Body Radiation Therapy
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Pancreatic Cancer
12/24
12/24
ALFAOMEGA, NCT04120935: Master Observational Trial

Recruiting
N/A
3000
Europe
Observation
IFOM ETS - The AIRC Institute of Molecular Oncology
Colorectal Cancer
07/25
12/25
Salvatore, Lisa
SAGITTARIUS, NCT06490536: The Sagittarius Trial

Recruiting
3
700
Europe
Oxaliplatin, Capecitabine, Folinic acid, Fluorouracil, Temozolomide, Irinotecan, Nivolumab, Ipilimumab, Trastuzumab, Pertuzumab, Panitumumab
IFOM ETS - The AIRC Institute of Molecular Oncology
Colon Cancer Stage II, Colon Cancer Stage III
03/26
09/28
AtezoTRIBE2, NCT06733038: FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

Recruiting
3
238
Europe
Atezolizumab, Bevacizumab, Irinotecan (CPT-11), Oxaliplatin, Leucovorin, Fluorouracil (5-FU)
Gruppo Oncologico del Nord-Ovest, Hoffmann-La Roche
Colorectal Cancer
04/28
04/29
PANThEON, NCT06897644: Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

Recruiting
3
340
Europe
Oxaliplatin, Irinotecan (CPT-11), Leucovorin, 5-FU (5-fluorouracil), gemcitabine, Nab-paclitaxel
Gruppo Oncologico del Nord-Ovest, Rising Tide Foundation
Pancreatic Adenocarcinoma Advanced or Metastatic
01/29
01/30
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
PURITY, NCT06037980: CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

Recruiting
2/3
300
Europe
Gemcitabine, Nab paclitaxel, Abraxane, Cisplatin, Curative Surgery, Capecitabine
Gruppo Oncologico del Nord-Ovest
Biliary Tract Cancer, Cholangiocarcinoma
12/28
01/29
BRICKET, NCT06578559: Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC

Recruiting
2
16
Europe
Cetuximab, Encorafenib
Gruppo Oncologico del Nord-Ovest, Merck Sharp & Dohme LLC, Pierre Fabre Laboratories
Colorectal Cancer
08/26
04/27
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting
2
154
Europe, Canada, Japan, US, RoW
Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A
GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd
Neoplasms, Rectal
11/26
10/29
ctDNA-GI, NCT06202131: Prospective Single-center Study About the Use of ctDNA in the Management of Patients With Tumors of the Gastrointestinal Tract

Recruiting
N/A
100
Europe
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Pancreas Cancer, Colon Cancer, Biliary Tract Cancer
11/28
11/28
SOCRATE, NCT06728358: The Future Management of Patients With Neoplasms of the Gastro-intestinal Tract

Active, not recruiting
N/A
300
Europe
Molecular analyses
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Pancreatic Adenocarcinoma, Cholangiocarcinoma, Colon Cancer
11/28
12/28
BABEL, NCT05942807: Observational Monocentric Study on Biliary Tract Cancer

Recruiting
N/A
560
Europe
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Biliary Tract Cancer
05/25
05/26
RMN-CRC, NCT05950503: Single-center Ambispective Observational Study on the Role of Magnetic Resonance Imaging (MRI) in the Evaluation of Patient Affected by Hepatic Metastases of Carcinoma of the Colorectal Cancer (CRC).

Recruiting
N/A
100
Europe
Hepatic MRI
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Colorectal Cancer
06/26
06/27
Imazio, Massimo
CMP-MYTHiC, NCT06158698: Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine

Recruiting
3
80
Europe
Colchicine, Treatment, Placebo
Niguarda Hospital, European Union, Ministry of Health, Italy, Mario Negri Institute for Pharmacological Research, University of Milano Bicocca
Cardiomyopathies, Myocarditis, Inflammatory Cardiomyopathy, Heart Failure, Ventricular Arrythmia
05/26
05/28
MYTHS-MR, NCT05974462: Trial (MYocarditis THerapy With Steroids in Patients With Mildly Reduced Ejection Fraction)

Recruiting
3
174
Europe
Methylprednisolone 125 MG, Solu-Medrol, IV saline solution 0.9%, sodium chloride
University Hospital, Antwerp, Niguarda Hospital
Acute Myocarditis
10/26
10/28
MYTHS, NCT05150704: - MYocarditis THerapy With Steroids

Recruiting
3
288
Europe, US, RoW
Methylprednisolone, saline solution
Niguarda Hospital, Ministry of Health, Italy, Istituto Di Ricerche Farmacologiche Mario Negri, University of Milano Bicocca, Regione Lombardia
Myocarditis Acute
03/28
12/28
RICMAF, NCT06806813: Italian Anderson Fabry Disease Cardiovascular Registry

Recruiting
N/A
800
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Fabry Disease
01/31
12/31
PERIPLO, NCT05925790: Clinical Phenotypes in Pericarditis: IL-1RA Antibodies and suPAR Levels

Recruiting
N/A
146
Europe
IL1RA Antibody Assay, suPAR Testing
ASST Fatebenefratelli Sacco, Fatebenefratelli Hospital, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Ospedale Galeazzi Sant'Ambrogio - IRCCS, Careggi Hospital, Azienda Ospedaliero Universitaria, Santa Maria della Misericordia di Udine, Italy, Children's Medical Hospital, University of Muenster, Muenster, Germany, University of Homburg, University Hospital Tuebingen
Pericarditis
07/25
12/25
Rizzato, Simona
NCT04810182: Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS

Completed
N/A
192
Europe
Regorafenib 40 MG Oral Tablet [STIVARGA]
Istituto Oncologico Veneto IRCCS
Glioblastoma Multiforme
12/23
12/23
Patriarca
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1594
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32
TAURUS, NCT06189833: Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT -

Recruiting
2
200
Europe
Daratumumab, JNJ-54767414, Bortezomib, Velcade, Lenalidomide, Dexamethasone
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
12/24
12/25
ERASMM, NCT06183489: Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

Recruiting
2
50
Europe
Elranatamab
Stichting European Myeloma Network, Pfizer
Smoldering Multiple Myeloma
07/27
07/31
Macerelli, Marianna
CHANCE, NCT03976518: Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies ( Trial)

Completed
2
43
Europe
Atezolizumab
Gruppo Oncologico Italiano di Ricerca Clinica, AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology, Istituto Toscano Tumori, YGHEA, CRO Division of Ecol Studio spa, Iqvia Pty Ltd, AOU S. Orsola Malpighi - Clinical Trial Office, Silvano Chiapparoli Logistica SpA, Roche SpA
Non-Small Cell Lung Cancer
02/24
02/24
CARRY-ON, NCT06663098: Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).

Recruiting
2
142
Europe
Atezolizumab, humanized IgG1 monoclonal antibody against PD-L1, Carboplatin, re-challenge chemotherapy, Etoposide
Gruppo Oncologico Italiano di Ricerca Clinica, Roche Pharma AG
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
08/28
06/29
I-STOP, NCT05418660: Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

Recruiting
N/A
300
Europe
Immunotherapy, Nivolumab, Pembrolizumab, Atezolizumab
University of Milano Bicocca, Azienda Ospedaliera San Gerardo di Monza
Non-small Cell Lung Cancer
11/24
11/24
APOLLO 11, NCT05550961: , Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch

Recruiting
N/A
1200
Europe
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Politecnico di Milano, Ospedale Policlinico San Martino, Insieme per i Pazienti di Oncologia Polmonare Onlus (IPOP), ASST Grande Ospedale Metropolitano Niguarda, University of Campania "Luigi Vanvitelli", Azienda Ospedaliera dei Colli, Fondazione IRCCS Policlinico San Matteo di Pavia, Azienda Ospedaliera S. Maria della Misericordia, Azienda Ospedaliera "Sant'Andrea", Azienda Ospedaliero Universitaria, Santa Maria della Misericordia di Udine, Italy, IRCCS Sacro Cuore Don Calabria di Negrar, Azienda Ospedaliero, Universitaria Ospedali Riuniti, Istituto Clinico Humanitas, Azienda Unità Sanitaria Locale della Romagna, Istituti Ospitalieri di Cremona
NSCLC, Cancer, Lung Cancer, Adenocarcinoma of Lung, Squamous Cell Lung Cancer
10/27
10/32
DEANA, CRISTIAN
TANDEM, NCT04132115: Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)

Recruiting
N/A
104
Europe
Piperacillin/tazobactam, Meropenem, Daptomycin, Ceftobiprole, Linezolid, Vancomycin, Fluconazol, Acyclovir, Gentamicins, Amikacin, Ganciclovir
Azienda Sanitaria-Universitaria Integrata di Udine
Therapeutic Drug Monitoring, Subarachnoid Hemorrhage, Intracerebral Hemorrhage
10/21
10/21
ODISSEA, NCT04860687: Quality of Life After COVID-19 Related Acute respIratory Distress Syndrome Among ICU Survivors Patients in Italy: the Study.

Recruiting
N/A
309
Europe
Azienda Sanitaria-Universitaria Integrata di Udine
Covid19, Post Traumatic Stress Disorder, Quality of Life
11/21
12/21
HPEEP, NCT05467332: Tracheal Positive Pressure During High Flow Nasal Oxygen Administration in Critically Ill Patients: a Physiologic Study.

Not yet recruiting
N/A
20
Europe
HIGH FLOW NASAL OXYGEN, AIRVO2, FISHER&PAYKEL
Azienda Sanitaria-Universitaria Integrata di Udine
Acute Respiratory Failure, High Flow Nasal Cannula, Critically Ill, Airway Disease, Positive End Expiratory Pressure, Diaphragm Disease
09/23
12/23
DINTESA, NCT06804421: Diagnosis and Treatment of Late Neurological Ischemic Deficit in Patients Suffering From Subarachnoid Hemorrhage.

Recruiting
N/A
1400
Europe
Fondazione IRCCS San Gerardo dei Tintori
Aneurysmal Subarachnoid Haemorrhage, Delayed Ischemic Neurological Deficit
10/25
10/26
OSSIGENA1V, NCT05718284: High Flow Nasal Cannula After Esophagectomy

Recruiting
N/A
320
Europe
AIRVO2, STANDARD CARE
Cristian Deana
Esophageal Cancer, Postoperative Pulmonary Atelectasis, Postoperative Pneumonia, Postoperative Pneumothorax, Postoperative Infection of Incision, Postoperative Acute Myocardial Infarction
10/24
01/25
TIMING-ICP, NCT05045105: Timing of Invasive Intracranial Pressure Monitoring Between Neurosurgeons and Intensive Care Physicians

Recruiting
N/A
64
Europe
Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication, Complications related to the maneuver between the two cohorts
Università degli Studi di Brescia
Intracranial Hypertension, Timing of Invasive Intracranial Pressure Monitoring
05/22
05/22
Muttini, Stefano
ALBIOSS-BAL, NCT03654001 / 2018-001582-16: ALBumin Italian Outcome Septic Shock-BALANCED Trial (ANCED)

Completed
3
1319
Europe
Albumin, Balanced, Ringer Lactate, Ringer Acetate, Crystalsol
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Istituto Di Ricerche Farmacologiche Mario Negri
Septic Shock
10/24
01/25
DINTESA, NCT06804421: Diagnosis and Treatment of Late Neurological Ischemic Deficit in Patients Suffering From Subarachnoid Hemorrhage.

Recruiting
N/A
1400
Europe
Fondazione IRCCS San Gerardo dei Tintori
Aneurysmal Subarachnoid Haemorrhage, Delayed Ischemic Neurological Deficit
10/25
10/26
Bozzarelli, Silvia
CASSANDRA, NCT04793932: Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG ( TRIAL)

Active, not recruiting
3
261
Europe
PAXG, mFOLFIRINOX, short-course chemotherapy, long-course chemotherapy
Associazione Italiana per lo Studio del Pancreas, High Research srl, Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Pancreas Ductal Adenocarcinoma
03/25
01/26
PANThEON, NCT06897644: Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

Recruiting
3
340
Europe
Oxaliplatin, Irinotecan (CPT-11), Leucovorin, 5-FU (5-fluorouracil), gemcitabine, Nab-paclitaxel
Gruppo Oncologico del Nord-Ovest, Rising Tide Foundation
Pancreatic Adenocarcinoma Advanced or Metastatic
01/29
01/30
Tascini, Carlo
AMMURAVID, NCT04832880 / 2020-001854-23: Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the Trial)

Not yet recruiting
3
4000
Europe
Baricitinib Oral Tablet [Olumiant], Olumiant, Remdesivir, Veklury, Dexamethasone
ASST Fatebenefratelli Sacco, AIFA
Covid19
03/22
12/22
MANTICO 2, NCT05321394: Non-inferiority Trial on Treatments in Early COVID-19

Completed
3
536
Europe
Sotrovimab, Tixagevimab Cilgavimab, Nirmatrelvir Ritonavir
Azienda Ospedaliera Universitaria Integrata Verona, Agenzia Italiana del Farmaco, Azienda Sanitaria-Universitaria Integrata di Udine
COVID-19
10/23
10/23
MARIO, NCT05178862 / 2022-000648-32: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Suspended
3
220
Europe, Canada, US, RoW
SCY-078, Ibrexafungerp, Fluconazole, Diflucan, Echinocandin, Caspofungin, Micafungin, Anidulafungin
Scynexis, Inc., SCYNEXIS, Inc.
Candidiasis, Invasive, Candidemia
06/24
08/24
FORTRESS, NCT02979951: Fosfomycin I.v. for Treatment of Severely Infected Patients

Recruiting
N/A
1000
Europe
Infectopharm Arzneimittel GmbH, INPADS GmbH, Dr. Oestreich + Partner GmbH
Bacterial Infections, Bone Diseases, Infectious, Osteomyelitis, Central Nervous System Bacterial Infections, Meningitis, Bacterial, Encephalitis, Brain Abscess, Urinary Tract Infections, Respiratory Tract Infections, Pneumonia, Bacterial, Skin Diseases, Bacterial, Soft Tissue Infections, Intraabdominal Infections, Sepsis, Bacteremia, Endocarditis, Bacterial
12/30
12/30
NCT05108883: Risk Stratification Using Midregional Proadrenomedullin in the ED

Completed
N/A
463
Europe
MR-proADM KRYPTOR
Brahms AG
Patients Presenting With Suspicion of Infection to the ED
11/23
11/23
Tan, Shao Weng Daniel
DOMENICA, NCT05201547 / 2021-002124-21: Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Recruiting
3
260
Europe, Canada, Japan, RoW
Carboplatin-Paclitaxel, Dostarlimab
ARCAGY/ GINECO GROUP, GlaxoSmithKline
Endometrial Cancer
04/26
10/29
LIBRETTO-001, NCT03157128 / 2017-000800-59: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Hourglass Apr 2022 - Dec 2022 : Approval in China for RET+NSCLC, medullary thyroid cancer and thyroid cancer
Hourglass Jan 2022 - Dec 2022 : Submission for lung cancer
Checkmark From LIBRETTO-001 trial in RET fusion-positive NSCLC
Aug 2020 - Aug 2020: From LIBRETTO-001 trial in RET fusion-positive NSCLC
Checkmark Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001]
More
Active, not recruiting
1/2
856
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Eli Lilly and Company, Loxo Oncology, Inc.
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
02/25
02/26
NCT03906331: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Approved for marketing
N/A
Europe, Japan, US, RoW
Selpercatinib, LOXO-292, LY3527723
Eli Lilly and Company, Eli Lilly and Company
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration
 
 
IMAC, NCT02078544: Integrated Molecular Analysis of Cancer

Recruiting
N/A
1800
RoW
Integrated Molecular Analysis
National University Hospital, Singapore
Cancer
12/24
 
Vescini, Fabio
START, NCT06164795: Sequential Therapies After Osteoanabolic Treatment

Recruiting
N/A
150
Europe
Zoledronate, zoledronic acid; zolendronate, Denosumab, Dmab, Teriparatide, TPTD, Romosozumab, Romo
424 General Military Hospital
Osteoporosis, Postmenopausal
12/25
12/25
OSTCOR, NCT05762549: Prevalence of Hidden Hypercortisolism in Osteoporosis

Recruiting
N/A
1000
Europe
Istituto Auxologico Italiano
Osteoporosis, Cortisol Excess
11/23
05/24
DOCOR, NCT05759637: Type 2 Diabetes, Obesity and Cortisol Excess

Recruiting
N/A
3200
Europe
1mg DST
Istituto Auxologico Italiano, University of Siena, Niguarda Hospital, Campus Bio-Medico University, Azienda Ospedaliero Universitaria, Santa Maria della Misericordia di Udine, Italy
Diabetes Mellitus, Type 2, Obesity, Cortisol; Hypersecretion
12/25
12/25
NCT06645951: Institution of an Italian Multicenter Database of Patients With Parathyroid Carcinoma or Atypical Parathyroid Adenoma

Not yet recruiting
N/A
300
Europe
F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore
Parathyroid Gland Carcinoma, Parathyroid Gland Atypical Adenoma
11/34
11/34
NCT06645899: Institution of an Italian Multicenter Database of Patients Affected by Hypoparathyroidism or Pseudohypoparathyroidism

Not yet recruiting
N/A
600
Europe
F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore
Hypoparathyroidism, Pseudo Hypoparathyroidism
11/34
11/34
ITCO, NCT04031339: Study of Clinical Outcomes of Thyroid Cancer

Recruiting
N/A
15000
Europe
Standard treatment
University of Roma La Sapienza, Italian Thyroid Cancer Observatory (ITCO) Foundation, Catholic University of the Sacred Heart
Thyroid Neoplasms
01/25
01/25
EURODEC, NCT05575167: Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)

Recruiting
N/A
125
Europe
Zoledronate or Alendronate, Calcium and vitamin D supplementation
424 General Military Hospital
Osteoporosis, Postmenopausal
11/26
11/26
Savoia, Marilena
LUNG, NCT05198375: Lung UltrasouNd Guided Surfactant Therapy in Preterm Infants ( Study)

Recruiting
N/A
668
Europe
Lung ultrasound score (LUS)
Azienda Ospedaliero-Universitaria Careggi
Respiratory Distress Syndrome, Newborn
01/24
07/24
Pittini, Carla
LUNG, NCT05198375: Lung UltrasouNd Guided Surfactant Therapy in Preterm Infants ( Study)

Recruiting
N/A
668
Europe
Lung ultrasound score (LUS)
Azienda Ospedaliero-Universitaria Careggi
Respiratory Distress Syndrome, Newborn
01/24
07/24
Casagrande, Maria Elena
ERASE-CRC, NCT05062889: Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

Recruiting
2
477
Europe
5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5FU, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule, Oxaliplatin FOLFOX and FOLFOXIRI schedule, Oxa, Oxaliplatin CAPOX schedule, L-Leucovorin, Lederfolin, Capecitabine, Irinotecan, Trifluridine/Tipiracil, FTD/TPI, Trastuzumab, Tucatinib
Gruppo Oncologico del Nord-Ovest, Servier, Foundation Medicine, Seagen Inc.
Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer, RAS Wild-type Colon Cancer
10/25
12/27
Vogrig, Alberto
PEA, NCT06019975: FDG-PET in the Diagnosis of Autoimmune Encephalitis

Recruiting
N/A
90
Europe
FDG-PET
University of Milano Bicocca
Autoimmune Encephalitis
03/24
04/24
Sabbata, De
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1594
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32
Leuzzi, Chiara
RICMAF, NCT06806813: Italian Anderson Fabry Disease Cardiovascular Registry

Recruiting
N/A
800
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Fabry Disease
01/31
12/31
Pella, Nicoletta
AtezoTRIBE2, NCT06733038: FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

Recruiting
3
238
Europe
Atezolizumab, Bevacizumab, Irinotecan (CPT-11), Oxaliplatin, Leucovorin, Fluorouracil (5-FU)
Gruppo Oncologico del Nord-Ovest, Hoffmann-La Roche
Colorectal Cancer
04/28
04/29
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lee
NCT05509868: Study of PBK_L1704 for the Treatment of Moderate to Severe Acute Pain After Bunionectomy in South Korea

Recruiting
3
225
RoW
PBK_L1704 0.35mg, PBK_L1704 0.5mg, Placebo
Pharmbio Korea Co., Ltd.
Acute Pain
12/22
12/22
STAMP, NCT05529056: Study of Atropine Therapeutic Effect on Myopic Progression

Recruiting
3
472
RoW
Atropine Sulfate 01, LPTAT01, Atropine Sulfate 02, LPTAT02, Atropine Sulfate 03, LPTAT03, Placebo, LPTAT04
LitePharmTech Co., Ltd.
Myopia, Children
06/23
12/23
NCT05128344 / 2021-003015-26: A Study to Evaluate Safety and Efficacy of AMZ002 Treatment, Compared With Vigabatrin in Participants With Infantile Spasms

Withdrawn
3
150
Europe, US, RoW
AMZ002 injectable solution, 0.5mg/mL, Vigabatrin, oral
Amzell
Spasms, Infantile
06/25
12/25
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1594
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32
CARTITUDE-6, NCT05257083 / 2021-003284-10: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Recruiting
3
750
Europe, Canada, Japan, US, RoW
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, JNJ-68284528, Cyclophosphamide, Fludarabine
Stichting European Myeloma Network, Janssen Research & Development, LLC
Multiple Myeloma
06/33
08/40
NCT05733624: Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis

Completed
2
116
RoW
SCAI-001 0.01% eyedrop, Cyclosporine 0.01%, SCAI-001 0.02% eyedrop, Cyclosporine 0.02%, Restasis 0.05% eyedrop, Cyclosporine 0.05%
SCAI Therapeutics
Dry Eye Syndromes
08/23
02/24
PLATINUM, NCT05338619: A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy

Recruiting
2
77
RoW
Lazertinib, LECLAZA
Sung Yong Lee, Yuhan Corporation
Non-small Cell Lung Cancer Stage III, EGFR Positive Non-small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer
03/26
03/26
WU-KONG1, NCT03974022: Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer with EGFR or HER2 Mutation

Active, not recruiting
1/2
315
Europe, Canada, Japan, US, RoW
Sunvozertinib, DZD9008
Dizal Pharmaceuticals
Non-Small Cell Lung Cancer
07/24
07/25
JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL

Completed
1/2
171
US, RoW
golidocitinib, AZD4205
Dizal Pharmaceuticals
Relapsed or Refractory Peripheral T Cell Lymphoma
10/23
02/24
NCT04746573: Effect of Natrox Oxygen Wound Therapy on Non-healing Wounds and Implication of Remote Monitoring and Telehealth for Management in the Home.

Completed
N/A
8
US
Natrox Topical Oxygen Therapy
Inotec AMD Limited, Salem VA Medical Center
Non-healing Wounds
05/22
05/22
JS-CT-2024-02, NCT06591221: The Effectiveness of Chuna Maintenance Therapy for Chronic Bothersome Neck Pain

Recruiting
N/A
250
RoW
Chuna Maintenance Therapy
Jaseng Medical Foundation
Neck Pain, Chronic Pain
12/25
12/25
ATEC.EOS-2402, NCT06659055: Bone Mineral Density Agreement Study Between EOSedge™ Versus Traditional DXA

Recruiting
N/A
214
US
DXA Imaging, EOSedge imaging
Alphatec Spine, Inc.
Healthy, Indicated for EOSedge Imaging
02/25
03/25
JS-CT-2024-04, NCT06572579: A Pilot Registry for Ultrasound-guided Pharmacopuncture

Recruiting
N/A
50
RoW
Ultrasound-guided pharmacopuncture treatment
Jaseng Medical Foundation
Neck Pain, Back Pain
12/25
12/25
NCT04701684: WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)

Recruiting
N/A
564
Europe, US, RoW
Direct to Angio Suite (DTAS) Philips' CBCT triage, Conventional CT/MR triage
Philips Clinical & Medical Affairs Global
Stroke, Acute
12/25
12/25
NCT06734858: Pivotal Trial of SAT-014 for Trauma and Stressor-Related Disorder Symptoms

Recruiting
N/A
110
RoW
SAT014, Control
S-Alpha Therapeutics, Inc.
Post-traumatic Stress Disorder, Adjustment Disorders
07/25
10/25
SAT001-KP-003, NCT06742268: Extension Study on Safety and Rebound Effect of SAT-001 for Myopia in Children

Recruiting
N/A
40
RoW
Single vision spectacles
S-Alpha Therapeutics, Inc.
Myopia
10/25
07/26
Minisini, Alessandro
NCT05299580 / 2019-004760-21: "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

Withdrawn
2
35
Europe
dabrafenib, Trametinib
Fondazione Melanoma Onlus, Novartis Farma S.p.A.
Melanoma
03/23
03/23
OVERTuRE, NCT06129786: Overcoming Therapy Resistance in ER+ Breast Cancer Patients: a Translational Project

Recruiting
N/A
74
Europe
Centro di Riferimento Oncologico - Aviano
Breast Cancer
05/26
05/26
Tamberi, Stefano
SAGITTARIUS, NCT06490536: The Sagittarius Trial

Recruiting
3
700
Europe
Oxaliplatin, Capecitabine, Folinic acid, Fluorouracil, Temozolomide, Irinotecan, Nivolumab, Ipilimumab, Trastuzumab, Pertuzumab, Panitumumab
IFOM ETS - The AIRC Institute of Molecular Oncology
Colon Cancer Stage II, Colon Cancer Stage III
03/26
09/28
PANThEON, NCT06897644: Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

Recruiting
3
340
Europe
Oxaliplatin, Irinotecan (CPT-11), Leucovorin, 5-FU (5-fluorouracil), gemcitabine, Nab-paclitaxel
Gruppo Oncologico del Nord-Ovest, Rising Tide Foundation
Pancreatic Adenocarcinoma Advanced or Metastatic
01/29
01/30
DOMENICA, NCT05201547 / 2021-002124-21: Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Recruiting
3
260
Europe, Canada, Japan, RoW
Carboplatin-Paclitaxel, Dostarlimab
ARCAGY/ GINECO GROUP, GlaxoSmithKline
Endometrial Cancer
04/26
10/29
PURITY, NCT06037980: CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

Recruiting
2/3
300
Europe
Gemcitabine, Nab paclitaxel, Abraxane, Cisplatin, Curative Surgery, Capecitabine
Gruppo Oncologico del Nord-Ovest
Biliary Tract Cancer, Cholangiocarcinoma
12/28
01/29
SENECA, NCT03387592 / 2016-000767-17: CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas

Terminated
2
53
Europe
CPT-11, Calcio levofolinate, 5-Fluorouracil, Capecitabine, Temozolomide
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Neuroendocrine Carcinoma
02/22
02/22
PANDORA, NCT04083365: Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer

Recruiting
2
100
Europe
Capecitabine, Radiotherapy, Durvalumab
AUSL Romagna Rimini, AstraZeneca, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
RECTAL CANCER
11/22
08/25
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Hourglass Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
Hourglass Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
Hourglass Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
Hourglass Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer
Completed
2
79
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IMGN853
AbbVie
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
01/24
12/24
BRICKET, NCT06578559: Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC

Recruiting
2
16
Europe
Cetuximab, Encorafenib
Gruppo Oncologico del Nord-Ovest, Merck Sharp & Dohme LLC, Pierre Fabre Laboratories
Colorectal Cancer
08/26
04/27
ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting
2
400
Europe
Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib
Fondazione per la Medicina Personalizzata
Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
12/24
06/25
ERASE-CRC, NCT05062889: Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

Recruiting
2
477
Europe
5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5FU, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule, Oxaliplatin FOLFOX and FOLFOXIRI schedule, Oxa, Oxaliplatin CAPOX schedule, L-Leucovorin, Lederfolin, Capecitabine, Irinotecan, Trifluridine/Tipiracil, FTD/TPI, Trastuzumab, Tucatinib
Gruppo Oncologico del Nord-Ovest, Servier, Foundation Medicine, Seagen Inc.
Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer, RAS Wild-type Colon Cancer
10/25
12/27
OVERPASS, NCT05861336 / 2022-001939-88: GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer

Withdrawn
2
34
Europe
Losartan, Gemcitabine, Nab paclitaxel, Stereotactic Body Radiation Therapy
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Pancreatic Cancer
12/24
12/24
ALFAOMEGA, NCT04120935: Master Observational Trial

Recruiting
N/A
3000
Europe
Observation
IFOM ETS - The AIRC Institute of Molecular Oncology
Colorectal Cancer
07/25
12/25
Salvatore, Lisa
SAGITTARIUS, NCT06490536: The Sagittarius Trial

Recruiting
3
700
Europe
Oxaliplatin, Capecitabine, Folinic acid, Fluorouracil, Temozolomide, Irinotecan, Nivolumab, Ipilimumab, Trastuzumab, Pertuzumab, Panitumumab
IFOM ETS - The AIRC Institute of Molecular Oncology
Colon Cancer Stage II, Colon Cancer Stage III
03/26
09/28
AtezoTRIBE2, NCT06733038: FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

Recruiting
3
238
Europe
Atezolizumab, Bevacizumab, Irinotecan (CPT-11), Oxaliplatin, Leucovorin, Fluorouracil (5-FU)
Gruppo Oncologico del Nord-Ovest, Hoffmann-La Roche
Colorectal Cancer
04/28
04/29
PANThEON, NCT06897644: Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

Recruiting
3
340
Europe
Oxaliplatin, Irinotecan (CPT-11), Leucovorin, 5-FU (5-fluorouracil), gemcitabine, Nab-paclitaxel
Gruppo Oncologico del Nord-Ovest, Rising Tide Foundation
Pancreatic Adenocarcinoma Advanced or Metastatic
01/29
01/30
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
PURITY, NCT06037980: CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

Recruiting
2/3
300
Europe
Gemcitabine, Nab paclitaxel, Abraxane, Cisplatin, Curative Surgery, Capecitabine
Gruppo Oncologico del Nord-Ovest
Biliary Tract Cancer, Cholangiocarcinoma
12/28
01/29
BRICKET, NCT06578559: Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC

Recruiting
2
16
Europe
Cetuximab, Encorafenib
Gruppo Oncologico del Nord-Ovest, Merck Sharp & Dohme LLC, Pierre Fabre Laboratories
Colorectal Cancer
08/26
04/27
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting
2
154
Europe, Canada, Japan, US, RoW
Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A
GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd
Neoplasms, Rectal
11/26
10/29
ctDNA-GI, NCT06202131: Prospective Single-center Study About the Use of ctDNA in the Management of Patients With Tumors of the Gastrointestinal Tract

Recruiting
N/A
100
Europe
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Pancreas Cancer, Colon Cancer, Biliary Tract Cancer
11/28
11/28
SOCRATE, NCT06728358: The Future Management of Patients With Neoplasms of the Gastro-intestinal Tract

Active, not recruiting
N/A
300
Europe
Molecular analyses
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Pancreatic Adenocarcinoma, Cholangiocarcinoma, Colon Cancer
11/28
12/28
BABEL, NCT05942807: Observational Monocentric Study on Biliary Tract Cancer

Recruiting
N/A
560
Europe
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Biliary Tract Cancer
05/25
05/26
RMN-CRC, NCT05950503: Single-center Ambispective Observational Study on the Role of Magnetic Resonance Imaging (MRI) in the Evaluation of Patient Affected by Hepatic Metastases of Carcinoma of the Colorectal Cancer (CRC).

Recruiting
N/A
100
Europe
Hepatic MRI
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Colorectal Cancer
06/26
06/27
Imazio, Massimo
CMP-MYTHiC, NCT06158698: Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine

Recruiting
3
80
Europe
Colchicine, Treatment, Placebo
Niguarda Hospital, European Union, Ministry of Health, Italy, Mario Negri Institute for Pharmacological Research, University of Milano Bicocca
Cardiomyopathies, Myocarditis, Inflammatory Cardiomyopathy, Heart Failure, Ventricular Arrythmia
05/26
05/28
MYTHS-MR, NCT05974462: Trial (MYocarditis THerapy With Steroids in Patients With Mildly Reduced Ejection Fraction)

Recruiting
3
174
Europe
Methylprednisolone 125 MG, Solu-Medrol, IV saline solution 0.9%, sodium chloride
University Hospital, Antwerp, Niguarda Hospital
Acute Myocarditis
10/26
10/28
MYTHS, NCT05150704: - MYocarditis THerapy With Steroids

Recruiting
3
288
Europe, US, RoW
Methylprednisolone, saline solution
Niguarda Hospital, Ministry of Health, Italy, Istituto Di Ricerche Farmacologiche Mario Negri, University of Milano Bicocca, Regione Lombardia
Myocarditis Acute
03/28
12/28
RICMAF, NCT06806813: Italian Anderson Fabry Disease Cardiovascular Registry

Recruiting
N/A
800
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Fabry Disease
01/31
12/31
PERIPLO, NCT05925790: Clinical Phenotypes in Pericarditis: IL-1RA Antibodies and suPAR Levels

Recruiting
N/A
146
Europe
IL1RA Antibody Assay, suPAR Testing
ASST Fatebenefratelli Sacco, Fatebenefratelli Hospital, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Ospedale Galeazzi Sant'Ambrogio - IRCCS, Careggi Hospital, Azienda Ospedaliero Universitaria, Santa Maria della Misericordia di Udine, Italy, Children's Medical Hospital, University of Muenster, Muenster, Germany, University of Homburg, University Hospital Tuebingen
Pericarditis
07/25
12/25
Rizzato, Simona
NCT04810182: Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS

Completed
N/A
192
Europe
Regorafenib 40 MG Oral Tablet [STIVARGA]
Istituto Oncologico Veneto IRCCS
Glioblastoma Multiforme
12/23
12/23
Patriarca
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1594
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32
TAURUS, NCT06189833: Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT -

Recruiting
2
200
Europe
Daratumumab, JNJ-54767414, Bortezomib, Velcade, Lenalidomide, Dexamethasone
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
12/24
12/25
ERASMM, NCT06183489: Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

Recruiting
2
50
Europe
Elranatamab
Stichting European Myeloma Network, Pfizer
Smoldering Multiple Myeloma
07/27
07/31
Macerelli, Marianna
CHANCE, NCT03976518: Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies ( Trial)

Completed
2
43
Europe
Atezolizumab
Gruppo Oncologico Italiano di Ricerca Clinica, AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology, Istituto Toscano Tumori, YGHEA, CRO Division of Ecol Studio spa, Iqvia Pty Ltd, AOU S. Orsola Malpighi - Clinical Trial Office, Silvano Chiapparoli Logistica SpA, Roche SpA
Non-Small Cell Lung Cancer
02/24
02/24
CARRY-ON, NCT06663098: Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).

Recruiting
2
142
Europe
Atezolizumab, humanized IgG1 monoclonal antibody against PD-L1, Carboplatin, re-challenge chemotherapy, Etoposide
Gruppo Oncologico Italiano di Ricerca Clinica, Roche Pharma AG
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
08/28
06/29
I-STOP, NCT05418660: Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

Recruiting
N/A
300
Europe
Immunotherapy, Nivolumab, Pembrolizumab, Atezolizumab
University of Milano Bicocca, Azienda Ospedaliera San Gerardo di Monza
Non-small Cell Lung Cancer
11/24
11/24
APOLLO 11, NCT05550961: , Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch

Recruiting
N/A
1200
Europe
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Politecnico di Milano, Ospedale Policlinico San Martino, Insieme per i Pazienti di Oncologia Polmonare Onlus (IPOP), ASST Grande Ospedale Metropolitano Niguarda, University of Campania "Luigi Vanvitelli", Azienda Ospedaliera dei Colli, Fondazione IRCCS Policlinico San Matteo di Pavia, Azienda Ospedaliera S. Maria della Misericordia, Azienda Ospedaliera "Sant'Andrea", Azienda Ospedaliero Universitaria, Santa Maria della Misericordia di Udine, Italy, IRCCS Sacro Cuore Don Calabria di Negrar, Azienda Ospedaliero, Universitaria Ospedali Riuniti, Istituto Clinico Humanitas, Azienda Unità Sanitaria Locale della Romagna, Istituti Ospitalieri di Cremona
NSCLC, Cancer, Lung Cancer, Adenocarcinoma of Lung, Squamous Cell Lung Cancer
10/27
10/32
DEANA, CRISTIAN
TANDEM, NCT04132115: Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)

Recruiting
N/A
104
Europe
Piperacillin/tazobactam, Meropenem, Daptomycin, Ceftobiprole, Linezolid, Vancomycin, Fluconazol, Acyclovir, Gentamicins, Amikacin, Ganciclovir
Azienda Sanitaria-Universitaria Integrata di Udine
Therapeutic Drug Monitoring, Subarachnoid Hemorrhage, Intracerebral Hemorrhage
10/21
10/21
ODISSEA, NCT04860687: Quality of Life After COVID-19 Related Acute respIratory Distress Syndrome Among ICU Survivors Patients in Italy: the Study.

Recruiting
N/A
309
Europe
Azienda Sanitaria-Universitaria Integrata di Udine
Covid19, Post Traumatic Stress Disorder, Quality of Life
11/21
12/21
HPEEP, NCT05467332: Tracheal Positive Pressure During High Flow Nasal Oxygen Administration in Critically Ill Patients: a Physiologic Study.

Not yet recruiting
N/A
20
Europe
HIGH FLOW NASAL OXYGEN, AIRVO2, FISHER&PAYKEL
Azienda Sanitaria-Universitaria Integrata di Udine
Acute Respiratory Failure, High Flow Nasal Cannula, Critically Ill, Airway Disease, Positive End Expiratory Pressure, Diaphragm Disease
09/23
12/23
DINTESA, NCT06804421: Diagnosis and Treatment of Late Neurological Ischemic Deficit in Patients Suffering From Subarachnoid Hemorrhage.

Recruiting
N/A
1400
Europe
Fondazione IRCCS San Gerardo dei Tintori
Aneurysmal Subarachnoid Haemorrhage, Delayed Ischemic Neurological Deficit
10/25
10/26
OSSIGENA1V, NCT05718284: High Flow Nasal Cannula After Esophagectomy

Recruiting
N/A
320
Europe
AIRVO2, STANDARD CARE
Cristian Deana
Esophageal Cancer, Postoperative Pulmonary Atelectasis, Postoperative Pneumonia, Postoperative Pneumothorax, Postoperative Infection of Incision, Postoperative Acute Myocardial Infarction
10/24
01/25
TIMING-ICP, NCT05045105: Timing of Invasive Intracranial Pressure Monitoring Between Neurosurgeons and Intensive Care Physicians

Recruiting
N/A
64
Europe
Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication, Complications related to the maneuver between the two cohorts
Università degli Studi di Brescia
Intracranial Hypertension, Timing of Invasive Intracranial Pressure Monitoring
05/22
05/22
Muttini, Stefano
ALBIOSS-BAL, NCT03654001 / 2018-001582-16: ALBumin Italian Outcome Septic Shock-BALANCED Trial (ANCED)

Completed
3
1319
Europe
Albumin, Balanced, Ringer Lactate, Ringer Acetate, Crystalsol
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Istituto Di Ricerche Farmacologiche Mario Negri
Septic Shock
10/24
01/25
DINTESA, NCT06804421: Diagnosis and Treatment of Late Neurological Ischemic Deficit in Patients Suffering From Subarachnoid Hemorrhage.

Recruiting
N/A
1400
Europe
Fondazione IRCCS San Gerardo dei Tintori
Aneurysmal Subarachnoid Haemorrhage, Delayed Ischemic Neurological Deficit
10/25
10/26
Bozzarelli, Silvia
CASSANDRA, NCT04793932: Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG ( TRIAL)

Active, not recruiting
3
261
Europe
PAXG, mFOLFIRINOX, short-course chemotherapy, long-course chemotherapy
Associazione Italiana per lo Studio del Pancreas, High Research srl, Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Pancreas Ductal Adenocarcinoma
03/25
01/26
PANThEON, NCT06897644: Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

Recruiting
3
340
Europe
Oxaliplatin, Irinotecan (CPT-11), Leucovorin, 5-FU (5-fluorouracil), gemcitabine, Nab-paclitaxel
Gruppo Oncologico del Nord-Ovest, Rising Tide Foundation
Pancreatic Adenocarcinoma Advanced or Metastatic
01/29
01/30
Tascini, Carlo
AMMURAVID, NCT04832880 / 2020-001854-23: Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the Trial)

Not yet recruiting
3
4000
Europe
Baricitinib Oral Tablet [Olumiant], Olumiant, Remdesivir, Veklury, Dexamethasone
ASST Fatebenefratelli Sacco, AIFA
Covid19
03/22
12/22
MANTICO 2, NCT05321394: Non-inferiority Trial on Treatments in Early COVID-19

Completed
3
536
Europe
Sotrovimab, Tixagevimab Cilgavimab, Nirmatrelvir Ritonavir
Azienda Ospedaliera Universitaria Integrata Verona, Agenzia Italiana del Farmaco, Azienda Sanitaria-Universitaria Integrata di Udine
COVID-19
10/23
10/23
MARIO, NCT05178862 / 2022-000648-32: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Suspended
3
220
Europe, Canada, US, RoW
SCY-078, Ibrexafungerp, Fluconazole, Diflucan, Echinocandin, Caspofungin, Micafungin, Anidulafungin
Scynexis, Inc., SCYNEXIS, Inc.
Candidiasis, Invasive, Candidemia
06/24
08/24
FORTRESS, NCT02979951: Fosfomycin I.v. for Treatment of Severely Infected Patients

Recruiting
N/A
1000
Europe
Infectopharm Arzneimittel GmbH, INPADS GmbH, Dr. Oestreich + Partner GmbH
Bacterial Infections, Bone Diseases, Infectious, Osteomyelitis, Central Nervous System Bacterial Infections, Meningitis, Bacterial, Encephalitis, Brain Abscess, Urinary Tract Infections, Respiratory Tract Infections, Pneumonia, Bacterial, Skin Diseases, Bacterial, Soft Tissue Infections, Intraabdominal Infections, Sepsis, Bacteremia, Endocarditis, Bacterial
12/30
12/30
NCT05108883: Risk Stratification Using Midregional Proadrenomedullin in the ED

Completed
N/A
463
Europe
MR-proADM KRYPTOR
Brahms AG
Patients Presenting With Suspicion of Infection to the ED
11/23
11/23
Tan, Shao Weng Daniel
DOMENICA, NCT05201547 / 2021-002124-21: Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Recruiting
3
260
Europe, Canada, Japan, RoW
Carboplatin-Paclitaxel, Dostarlimab
ARCAGY/ GINECO GROUP, GlaxoSmithKline
Endometrial Cancer
04/26
10/29
LIBRETTO-001, NCT03157128 / 2017-000800-59: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Hourglass Apr 2022 - Dec 2022 : Approval in China for RET+NSCLC, medullary thyroid cancer and thyroid cancer
Hourglass Jan 2022 - Dec 2022 : Submission for lung cancer
Checkmark From LIBRETTO-001 trial in RET fusion-positive NSCLC
Aug 2020 - Aug 2020: From LIBRETTO-001 trial in RET fusion-positive NSCLC
Checkmark Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001]
More
Active, not recruiting
1/2
856
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Eli Lilly and Company, Loxo Oncology, Inc.
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
02/25
02/26
NCT03906331: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Approved for marketing
N/A
Europe, Japan, US, RoW
Selpercatinib, LOXO-292, LY3527723
Eli Lilly and Company, Eli Lilly and Company
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration
 
 
IMAC, NCT02078544: Integrated Molecular Analysis of Cancer

Recruiting
N/A
1800
RoW
Integrated Molecular Analysis
National University Hospital, Singapore
Cancer
12/24
 
Vescini, Fabio
START, NCT06164795: Sequential Therapies After Osteoanabolic Treatment

Recruiting
N/A
150
Europe
Zoledronate, zoledronic acid; zolendronate, Denosumab, Dmab, Teriparatide, TPTD, Romosozumab, Romo
424 General Military Hospital
Osteoporosis, Postmenopausal
12/25
12/25
OSTCOR, NCT05762549: Prevalence of Hidden Hypercortisolism in Osteoporosis

Recruiting
N/A
1000
Europe
Istituto Auxologico Italiano
Osteoporosis, Cortisol Excess
11/23
05/24
DOCOR, NCT05759637: Type 2 Diabetes, Obesity and Cortisol Excess

Recruiting
N/A
3200
Europe
1mg DST
Istituto Auxologico Italiano, University of Siena, Niguarda Hospital, Campus Bio-Medico University, Azienda Ospedaliero Universitaria, Santa Maria della Misericordia di Udine, Italy
Diabetes Mellitus, Type 2, Obesity, Cortisol; Hypersecretion
12/25
12/25
NCT06645951: Institution of an Italian Multicenter Database of Patients With Parathyroid Carcinoma or Atypical Parathyroid Adenoma

Not yet recruiting
N/A
300
Europe
F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore
Parathyroid Gland Carcinoma, Parathyroid Gland Atypical Adenoma
11/34
11/34
NCT06645899: Institution of an Italian Multicenter Database of Patients Affected by Hypoparathyroidism or Pseudohypoparathyroidism

Not yet recruiting
N/A
600
Europe
F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore
Hypoparathyroidism, Pseudo Hypoparathyroidism
11/34
11/34
ITCO, NCT04031339: Study of Clinical Outcomes of Thyroid Cancer

Recruiting
N/A
15000
Europe
Standard treatment
University of Roma La Sapienza, Italian Thyroid Cancer Observatory (ITCO) Foundation, Catholic University of the Sacred Heart
Thyroid Neoplasms
01/25
01/25
EURODEC, NCT05575167: Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)

Recruiting
N/A
125
Europe
Zoledronate or Alendronate, Calcium and vitamin D supplementation
424 General Military Hospital
Osteoporosis, Postmenopausal
11/26
11/26
Savoia, Marilena
LUNG, NCT05198375: Lung UltrasouNd Guided Surfactant Therapy in Preterm Infants ( Study)

Recruiting
N/A
668
Europe
Lung ultrasound score (LUS)
Azienda Ospedaliero-Universitaria Careggi
Respiratory Distress Syndrome, Newborn
01/24
07/24
Pittini, Carla
LUNG, NCT05198375: Lung UltrasouNd Guided Surfactant Therapy in Preterm Infants ( Study)

Recruiting
N/A
668
Europe
Lung ultrasound score (LUS)
Azienda Ospedaliero-Universitaria Careggi
Respiratory Distress Syndrome, Newborn
01/24
07/24
Casagrande, Maria Elena
ERASE-CRC, NCT05062889: Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

Recruiting
2
477
Europe
5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5FU, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule, Oxaliplatin FOLFOX and FOLFOXIRI schedule, Oxa, Oxaliplatin CAPOX schedule, L-Leucovorin, Lederfolin, Capecitabine, Irinotecan, Trifluridine/Tipiracil, FTD/TPI, Trastuzumab, Tucatinib
Gruppo Oncologico del Nord-Ovest, Servier, Foundation Medicine, Seagen Inc.
Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer, RAS Wild-type Colon Cancer
10/25
12/27
Vogrig, Alberto
PEA, NCT06019975: FDG-PET in the Diagnosis of Autoimmune Encephalitis

Recruiting
N/A
90
Europe
FDG-PET
University of Milano Bicocca
Autoimmune Encephalitis
03/24
04/24
Sabbata, De
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1594
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32
Leuzzi, Chiara
RICMAF, NCT06806813: Italian Anderson Fabry Disease Cardiovascular Registry

Recruiting
N/A
800
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Fabry Disease
01/31
12/31
Pella, Nicoletta
AtezoTRIBE2, NCT06733038: FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

Recruiting
3
238
Europe
Atezolizumab, Bevacizumab, Irinotecan (CPT-11), Oxaliplatin, Leucovorin, Fluorouracil (5-FU)
Gruppo Oncologico del Nord-Ovest, Hoffmann-La Roche
Colorectal Cancer
04/28
04/29

Download Options